Potential solutions for manufacture of CAR T cells in cancer immunotherapy

CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature communications 2022-09, Vol.13 (1), p.5225-5225, Article 5225
Hauptverfasser:	Blache, Ulrich, Popp, Georg, Dünkel, Anna, Koehl, Ulrike, Fricke, Stephan
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/580 692/4028/67/580 Antigens Automation Cancer Cancer immunotherapy Cell therapy Comment Cytokines Good Manufacturing Practice Graft versus host disease Hematology Humanities and Social Sciences Immune system Immunotherapy Lymphocytes Lymphocytes T Manufacturing multidisciplinary New technology Patients Pharmaceutical industry Science Science (multidisciplinary) T cell receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.
ISSN:	2041-1723 2041-1723
DOI:	10.1038/s41467-022-32866-0